The agenda will feature speakers who will share what achieving gender parity means to them, as well as highlight the groundbreaking work being done at large organizations.

In this participatory workshop, participants will learn to convey information in a way that can be heard, digested and applied moving forward, creating a positive environment that fosters learning and receptivity to feedback.

Proof-of-concept study in first-line mRCC (a type of kidney cancer) shows that Tecentriq and Avastin can be combined with a manageable safety profile.

Celgene Corporation announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod – an investigational oral, selective S1P 1 and 5 receptor modulator – in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) β-1a (Avonex).

AstraZeneca announced positive results from its Phase III OlympiAD trial comparing LYNPARZA (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations.

June Laffey of McCann Health is the 2017 Pharma Lions Jury President and Serviceplan Health & Life’s Mike Rogers is the Health & Wellness Lions Jury President.

Leman Micro Devices has announced that its Health Sensor & App – the only smartphone-integrated solution that measures blood pressure and other vital signs with medical accuracy – is being readied for submission to FDA and other regulators worldwide.

Lurking behind all the sound and fury in the political realm, 2017 is bringing new opportunities to marketers that have nothing at all to do with orange hair. A whole generation of technologies are growing to maturity together – predictive targeting, virtual reality, behavioral science, interactive video, big data, and more – all of which are transforming the ways in which brands can communicate with their audiences. But of course politics will matter too in this Year One of the Trump administration, as the continuing debate over drug pricing and the impact of the new president’s policies on the pharma industry remain very much up in the ai

There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.

Despite the general anxiety over the impact of President Trump’s policies, when it comes to pharmaceutical sales forces, little of what he does will actually affect pharma sales-force strategies. The trends that are continuing to play out are declining rep access, the size of pharma sales forces, and the struggle with the concept of key account management, as well as trying to figure out how reps should be compensated.